Spyre Therapeutics (SYRE) Invested Capital: 2015-2025
Historic Invested Capital for Spyre Therapeutics (SYRE) over the last 10 years, with Sep 2025 value amounting to $466.1 million.
- Spyre Therapeutics' Invested Capital rose 32.37% to $466.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $466.1 million, marking a year-over-year increase of 32.37%. This contributed to the annual value of $542.9 million for FY2024, which is 192.81% up from last year.
- Spyre Therapeutics' Invested Capital amounted to $466.1 million in Q3 2025, which was down 9.61% from $515.7 million recorded in Q2 2025.
- Spyre Therapeutics' Invested Capital's 5-year high stood at $542.9 million during Q4 2024, with a 5-year trough of -$237.9 million in Q3 2023.
- In the last 3 years, Spyre Therapeutics' Invested Capital had a median value of $352.1 million in 2024 and averaged $261.1 million.
- As far as peak fluctuations go, Spyre Therapeutics' Invested Capital crashed by 452.15% in 2023, and later soared by 977.07% in 2024.
- Spyre Therapeutics' Invested Capital (Quarterly) stood at $83.9 million in 2021, then tumbled by 40.07% to $50.3 million in 2022, then soared by 268.56% to $185.4 million in 2023, then surged by 192.81% to $542.9 million in 2024, then surged by 32.37% to $466.1 million in 2025.
- Its Invested Capital was $466.1 million in Q3 2025, compared to $515.7 million in Q2 2025 and $525.4 million in Q1 2025.